von Willebrand Factor

A high-molecular-weight plasma protein, produced by endothelial cells and megakaryocytes, that is part of the factor VIII/von Willebrand factor complex. The von Willebrand factor has receptors for collagen, platelets, and ristocetin activity as well as the immunologically distinct antigenic determinants. It functions in adhesion of platelets to collagen and hemostatic plug formation. The prolonged bleeding time in VON WILLEBRAND DISEASES is due to the deficiency of this factor.
Also Known As:
Factor VIIIR-Ag; Factor VIIIR-RCo; Plasma Factor VIII Complex; Ristocetin Cofactor; Ristocetin-Willebrand Factor; von Willebrand Protein; Factor VIII Related Antigen; Factor VIIIR Ag; Factor VIIIR RCo; Ristocetin Willebrand Factor; Factor VIII-Related Antigen
Networked: 4766 relevant articles (87 outcomes, 433 trials/studies)

Relationship Network

Bio-Agent Context: Research Results


1. Lip, Gregory Y H: 47 articles (01/2014 - 07/2002)
2. Blann, A D: 36 articles (10/2014 - 02/2000)
3. Federici, Augusto B: 32 articles (06/2014 - 02/2002)
4. Federici, A B: 31 articles (05/2015 - 01/2000)
5. Castaman, G: 30 articles (05/2014 - 01/2000)
6. Blann, Andrew D: 29 articles (01/2014 - 07/2002)
7. Budde, Ulrich: 28 articles (01/2015 - 04/2002)
8. Mannucci, P M: 26 articles (05/2015 - 01/2000)
9. Budde, U: 25 articles (07/2014 - 01/2000)
10. Favaloro, Emmanuel J: 24 articles (12/2014 - 04/2002)

Related Diseases

1. von Willebrand Diseases (von Willebrand's Disease)
2. Hemorrhage
3. Thrombosis (Thrombus)
01/22/2013 - "In this study, we provide evidence that plaque geometries result in fluid mechanical conditions that promote platelet aggregation and thrombus formation by increased accumulation and activity of von Willebrand factor (vWF) at poststenotic sites. "
06/01/2009 - "More over, in an in vitro study when whole blood was circulated both at venous and arterial shear conditions and shear rate was adjusted according to the blood viscosity, platelet aggregate/thrombus formation was characteristic on surfaces covered with purified von Willebrand factor while in case of controls the surface was covered with single platelets or platelet monolayer. "
07/01/2007 - "The recognition of VWD as a distinct entity in blood and the cloning of the von Willebrand factor (VWF) gene in the 1980s encouraged both phenotypic and genotypic studies, culminating in 1994 with the recognition, by the VWF subcommittee of the Scientific and Standardization Committee (SSC) of International Society of Thrombosis and Haemostasy (ISTH), of three types of VWD, characterized by severe plasma VWF deficiency (type 3), functionally deficient plasma VWF (type 2) and reduced (below normal) levels of plasma VWF, which is functionally essentially normal (type 1; 70% of all cases). "
05/17/2002 - "The purpose of this study was to investigate the antithrombotic effect and bleeding time prolongation of AJW200, a humanized monoclonal antibody to von Willebrand factor (vWF), in a canine model of coronary arterial thrombosis. "
07/01/2015 - "An unbalance between the platelet-adhesive protein von Willebrand factor (VWF) and its cleaving protease ADAMTS13 is a risk factor for thrombosis. "
4. Thrombotic Thrombocytopenic Purpura
5. Hemophilia A (Haemophilia)

Related Drugs and Biologics

1. Factor VIII (Coagulation Factor VIII)
2. Antigens
3. Collagen
4. von Willebrand Factor
5. thymidine 5'-triphosphate (TTP)
6. Deamino Arginine Vasopressin (Desmopressin)
7. C-Reactive Protein
8. Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
9. Tissue Plasminogen Activator (Alteplase)
10. P-Selectin

Related Therapies and Procedures

1. Plasma Exchange
2. Homologous Transplantation (Allograft)
3. Prostheses and Implants (Prosthesis)
4. Transplants (Transplant)
5. Peritoneal Dialysis